Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for later this year.
The post BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing appeared first on MedCity News.
